Toxic epidermal necrosis - Giftige Epidermale Nekrosehttps://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis
Giftige Epidermale Nekrose (Toxic epidermal necrosis) is 'n tipe ernstige velreaksie. Vroeë simptome sluit koors en griepagtige simptome in. 'n Paar dae later begin die vel blase en skil en vorm pynlike skilferige areas. Dit is belangrik dat slymvliese, soos die mond, ook tipies betrokke is. Komplikasies sluit in dehidrasie, sepsis, longontsteking en veelvuldige orgaanversaking.

Die mees algemene oorsaak is sekere medikasie soos lamotrigien, karbamazepien, allopurinol, sulfonamied antibiotika en nevirapien. Risikofaktore sluit in MIV en sistemiese lupus erythematosus. Behandeling vind gewoonlik in die hospitaal plaas, soos in 'n brandwondeenheid of intensiewesorgeenheid.

Behandeling
Dit is 'n ernstige siekte, so as jou lippe of mond aangetas is of jou vel blaas, sien jou dokter so gou as moontlik.
Verdagte dwelms moet gestaak word. (bv. antibiotika, nie-steroïdale anti-inflammatoriese middels)

☆ In die 2022 Stiftung Warentest-resultate van Duitsland was verbruikerstevredenheid met ModelDerm net effens laer as met betaalde telemedisyne-konsultasies.
  • Kenmerkende velverlies van Giftige Epidermale Nekrose (Toxic epidermal necrosis)
  • TENS ― dag 10
  • Necrolysis epidermalis toxica
  • Vroeë stadium blase kan vinnig vorder om die hele liggaam binne 'n paar dae te betrek.
References Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management 34577817 
NIH
Stevens-Johnson Syndrome (SJS) en Toxic Epidermal Necrolysis (TEN) is seldsame toestande waar die vel uitgebreide nekrose en vergieting ervaar. Wat behandeling betref, is siklosporien hoogs effektief vir SJS, terwyl 'n kombinasie van binneaarse immunoglobulien (IVIg) en kortikosteroïede die beste werk vir gevalle van SJS en TIEN.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
 Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 36469487
Toxic epidermal necrolysis (TEN) is 'n ernstige velreaksie wat veroorsaak word deur sekere medikasie en immuunstelselaktiwiteit, wat lei tot grootskaalse loslating van die buitenste vellaag (epidermis) , wat meer as 30% van die liggaam se oppervlak affekteer. TEN het 'n sterftesyfer van meer as 20%, dikwels as gevolg van infeksies en asemhalingsprobleme. Om die medikasie wat die reaksie veroorsaak te stop, ondersteunende sorg te verskaf en bykomende behandelings te gebruik, kan die uitkoms verbeter. Onlangse studies het getoon dat middels soos siklosporien, tumornekrosefaktor alfa-inhibeerders, en 'n kombinasie van binneaarse immuunglobulien en kortikosteroïede nuttig kan wees, gebaseer op gerandomiseerde beheerde proewe en ontledings van veelvuldige studies.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
 Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review 32520664 
NIH
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.